Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24843677 | 0.82 | PDE2A (0.35) | — | |
| SCHEMBL21361812 | 0.74 | SNCA (0.31) | — | |
| SCHEMBL14908674 | 0.72 | L3MBTL1 (0.40) | GSK3BNPC1ALDH1A1LMNAGAA | |
| SCHEMBL24843288 | 0.72 | ADORA1 (0.33) | NPC1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL23169977 | 0.69 | PDE2A (0.32) | — | |
| SCHEMBL20759659 | 0.68 | MGAM (0.36) | GAA | |
| SCHEMBL14911208 | 0.68 | PIK3CA (0.38) | ALDH1A1L3MBTL1 | |
| SCHEMBL21354079 | 0.67 | L3MBTL1 (0.47) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL30690865 | 0.67 | L3MBTL1 (0.47) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL24843909 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765008-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-10894052-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-19 | — | — | US | disclosed |
| US-20190282584-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| WO-2019178590-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894052-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | GSK3B 643/4885NPC1 4162/4885ALDH1A1 3736/4885 |
| US-20190282584-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | GSK3B 643/4885NPC1 4162/4885ALDH1A1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.